查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2072251

癌症代謝療法市場（第二版）：按治療類型、給藥途徑、目標疾病/適應症和地區分類，以及治療藥物的銷售預測 - 趨勢和預測（2026-2035 年）

Cancer Metabolism Based Therapeutics Market (2nd Edition) Distribution by Type of Modality, Route of Administration, Target Disease Indication, Geographical Regions and Sales Forecast of Therapies - Trends and Forecast 2026-2035
出版日期: | 出版商: Roots Analysis | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

癌症代謝療法市場：概述

預計癌症代謝療法市場規模將從今年的 37 億美元成長到 2035 年的 263 億美元，在預測期內（到 2035 年）的複合年成長率為 24.3%。

癌症代謝療法市場—成長與趨勢

癌症仍然是全球範圍內的一項重大健康負擔，每年影響著數百萬人。癌細胞的增殖和進展是由再程式化驅動的，這個過程使癌細胞能夠以不同於正常細胞的方式利用營養物質。這種再程式化的特徵是主要代謝途徑的改變，包括葡萄糖吸收增加（與瓦伯格效應相關）、粒線體功能受損以及對麩醯胺酸和脂質等營養物質的依賴性增強。這些改變共同構成了癌細胞與健康細胞相比獨特的代謝特徵。

在1920世紀中期，奧托·瓦爾貝格關於癌症代謝的開創性研究表明，腫瘤組織優先利用有氧糖解。這項發現激發了工業界和相關人員對腫瘤生存所必需的重編程代謝路徑研究的濃厚興趣。隨後的研究工作主要集中在鑑定和表徵參與三羧酸循環（TCA循環）、脂質生物合成、胺基酸、磷酸戊糖和核苷酸代謝等路徑的關鍵酶。

這些基礎知識推動了癌症代謝療法的發展和進步。這些療法透過有效靶向和抑制腫瘤特異性代謝通路，展現出抑制細胞不受控制增殖的巨大潛力。在令人鼓舞的治療效果的驅動下，各公司正在建立眾多策略合作夥伴關係，以加速全球癌症代謝療法市場的研發活動。隨著候選藥物進入後期臨床開發階段，預計這些合作關係將進一步活性化，從而在未來幾年內支撐市場的強勁成長。

成長要素－市場擴張的策略促進因素

代謝標靶癌症治療市場的成長主要得益於精準醫療方法的日益普及，這些方法針對與個別腫瘤特徵相關的特定代謝路徑。這使得開發更具個人化和療效的治療策略成為可能。這項轉變促使製藥公司拓展開發平臺，以滿足日益成長的標靶癌症治療需求。同時，全球癌症負擔持續急劇增加，每年新患者約2000萬例，死亡病例超過1000萬例。此外，人口成長和人口趨勢表明，到2050年，年發病率可能超過3500萬例。這種盛行率的激增凸顯了對創新治療方案的迫切需求，例如代謝標靶癌症治療，這類療法著重於癌細胞中重編程的代謝通路，與傳統療法相比，能夠實現更高的療效和更佳的個人化。

市場挑戰－阻礙進展的主要障礙

癌症代謝療法市場面臨著巨大的挑戰，這主要是由於標靶特異性的限制以及腫瘤代謝固有的複雜性。由於癌細胞和正常細胞通常共享重疊的代謝通路，因此脫靶效應十分常見，許多現有療法都存在著標靶特異性不足和毒性過高的問題。這些問題導致臨床試驗失敗率高、核准受到監管限制、研發成本增加、商業性可行性受限。此外，癌細胞的代謝可塑性構成了另一道障礙，使其能夠動態適應微環境壓力，例如營養缺乏和缺氧。鑑於腫瘤代謝的高度異質性和靈活性，這種適應性使得有效靶向單一代謝路徑變得異常困難。因此，由於基因突變和蛋白質表現圖譜的差異，化療和放射線治療等傳統療法的療效存在個別差異，僅對部分患者有效。這種差異凸顯了腫瘤學領域對精準化和個人化治療方法的迫切需求。

癌症代謝療法市場：關鍵洞察

本報告詳細分析了癌症代謝療法市場的現狀，並指出了該行業的潛在成長機會。報告的主要發現包括：

  • 目前，近 250 個癌症代謝療法計畫利用癌細胞獨特的代謝脆弱性，針對多種癌症進行治療。
基於癌症代謝的治療市場-IMG1
  • 近 90% 的代謝為基礎的癌症治療計畫正在進行臨床試驗，其中大多數（52%）正在 II 期臨床試驗中進行評估。
  • 2025 年，相當一部分試驗（約 30%）已開始招募受試者。此外，超過 70% 的試驗目前正在招募受試者，以研究癌症代謝療法。
  • 在過去兩年中，代謝類癌症治療市場約65%的合約已經簽訂。尤其值得注意的是，其中絕大多數合約（超過50%）是由總部位於北美的公司簽訂的。
基於癌症代謝的治療市場-IMG2
  • 癌症發病率上升、標靶治療的進步以及研發資金的增加正在推動市場成長。
  • 隨著癌症發生率的上升和腫瘤代謝研究的重大進展，預計到 2035 年，全球癌症代謝療法市場將以 24.3% 的複合年成長率成長。
基於癌症代謝的治療市場-IMG3
  • 預計在預測期內，美國癌症代謝療法市場將以穩定的複合年成長率成長，這主要得益於臨床應用的增加和癌症代謝療法的日益普及。
  • 成熟的市場參與企業、癌症患者數量的快速成長以及技術的不斷進步，預計將推動美國癌症代謝療法市場實現顯著成長。

基於代謝的癌症藥物市場

市場規模和機會分析是根據以下參數進行細分的：

治療類型

  • 小分子藥物
  • 生物製藥

透過行政途徑

  • 口服
  • 靜脈
  • 肌肉內部

按目標疾病/適應症

  • 乳癌
  • 非小細胞肺癌
  • 急性骨髓性白血病
  • 腦腫瘤
  • 膽管癌
  • 膽管癌
  • 骨髓發育不良症候群
  • 惡性間皮癌
  • 軟組織肉瘤
  • 肝細胞癌
  • 胰臟癌

按地區

  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他地區

治療藥物銷售預測

  • 達拉克森·拉西布
  • 吉達曲布
  • 奧羅莫拉西布
  • 伊那博利西布
  • 硼拉西地尼
  • STX-478
  • AZD 5363
  • AG-120
  • 塞帕卡替尼
  • ADI-PEG 20
  • 奧古斯蒂羅
  • 塔雷替尼
  • 皮克利
  • TAS-120
  • 萊斯利迪亞
  • AG-221

癌症代謝療法市場—主要細分市場

在以代謝為基礎的癌症療法市場中，哪種給藥途徑佔最大的市場佔有率？

預計到2035年，口服給藥途徑將佔約85%的市場佔有率，並在整個預測期內保持強勁成長。這一優勢歸功於其非侵入性、給藥方便性以及與其他給藥途徑相比更高的患​​遵守用藥。同時，肌肉注射給藥途徑預計將實現更高的複合年成長率，因為它能夠使代謝抑制劑在較長時間內持續、可控地釋放，從而維持穩定的治療濃度並減少給藥頻率。

哪種管理方式的市佔率最大？

市場分析預測，到2035年，小分子藥物將在癌症代謝治療市場佔最大佔有率。其主導地位得益於其已證實的療效、給藥方便、生產成本低廉以及良好的安全性。

區域市場分析：哪些地區成長最快？

北美：最大的區域市場

預計到2035年，北美將佔全球市場佔有率的45%以上，這主要得益於美國對癌症代謝療法的需求不斷成長，以及該地區眾多成熟的治療研發公司的強大實力。此外，近年來，多家領先製造商已擴大其研發和生產能力，以滿足該地區日益成長的需求。

亞太地區：成長最快的區域市場

在亞太地區，癌症代謝療法市場預計到2035年將保持較高的複合年成長率，這主要得益於對新型癌症代謝療法研發投入的增加，以及有利於具備專業能力的研發公司的法規結構。此外，該地區患者數量的不斷成長也擴大了藥品和醫療保健產品的潛在市場，從而推動了整體市場成長。

代謝類癌症治療市場中一些主要公司的例子

  • Bristol Myers Squibb
  • Eli Lilly
  • Novartis
  • Polaris
  • Roche

癌症代謝療法市場：研究範圍

  • 市場規模和機會分析：本報告詳細分析了癌症代謝療法市場，重點關注關鍵市場細分，例如 [A] 治療類型，[B] 給藥途徑，[C] 靶向疾病，[D] 地區，以及 [E] 治療銷售預測。
  • 代謝類癌症治療市場概覽：除了對代謝類癌症治療的整體市場概覽進行詳細評估外，本報告還包括有關幾個相關參數的信息，例如 [A] 代謝途徑，[B] 靶點，[C] 靶向疾病，[D] 給藥途徑，[E] 治療類型，[F] 治療類型，[G] 藥物名稱，[H] 年份，總部[J] 年份，總部[J] 年度藥物名稱，[H] 年份，總部[J] 年份，總部[J
  • 公司簡介：詳細介紹總部位於北美、歐洲和亞太地區的領先公司。這些簡介是基於多個參數編製而成，包括[A] 成立年份，[B] 總部所在地，[C]產品系列，[D] 近期發展，以及[E] 未來展望。
  • 臨床試驗分析：我們根據相關參數對已完成和正在進行的癌症代謝療法臨床試驗進行詳細分析，這些參數包括：[A] 試驗註冊年份，[B]實驗狀況，[C] 試驗階段，[D] 入組患者人數，[E] 試驗設計，[F] 申辦方類型，[G] 患者性別，[H] 最活躍的產業和非產業性別，[H] 參與者
  • 夥伴關係與合作研究分析：本分析檢視了該領域相關人員建立的夥伴關係。它包括各種夥伴關係模式的概述，以及基於[A]夥伴關係年份、[B]夥伴關係類型和[C]區域分析的詳細夥伴關係分析。
  • 市場影響分析：本部分詳細分析可能影響市場成長的因素，包括關鍵促進因素、潛在限制因素、新興機會和現有挑戰的識別與分析。

目錄

第1章 背景

第2章：調查方法

第3章 市場動態

第4章 宏觀經濟指標

第5章摘要整理

第6章：引言

  • 代謝相關癌症療法概述
  • 與癌細胞相關的主要代謝變化
  • 與癌症相關的主要代謝途徑
  • 基於代謝的抗癌藥物的優勢
  • 癌症代謝療法所面臨的挑戰
  • 未來展望

第7章 市場狀況

  • 調查方法和關鍵參數
  • 癌症代謝療法：市場現狀
  • 癌症代謝療法：研發現狀

第8章：公司簡介

  • 章節概要
  • AstraZeneca
  • Bristol Myers Squibb
  • Cornerstone Pharmaceuticals
  • Eli Lilly
  • Novartis
  • Polaris
  • Roche
  • Servier

第9章：臨床試驗分析

  • 調查方法和關鍵參數
  • 癌症代謝療法：臨床試驗分析

第10章夥伴關係與合作

第11章 市場影響分析

  • 章節概要
  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 市場挑戰

第12章 全球代謝標靶癌症治療市場

第13章：以代謝為基礎的癌症治療市場（依治療類型分類）

第14章：代謝為基礎的癌症治療藥物市場（依給藥途徑分類）

第15章 以代謝為基礎的癌症治療市場：以標靶疾病分類

第16章 以代謝為基礎的癌症治療藥物市場（按地區分類）

第17章 北美代謝標靶癌症治療市場

第18章 歐洲代謝標靶癌症治療市場

第19章 亞太地區以代謝為基礎的癌症治療市場

第20章：以代謝為基礎的癌症治療市場及藥品銷售預測

  • 已通過核准的癌症代謝療法：銷售預測
    • Daraxonrasib：銷售預測
    • Gedatricib：銷售預測
    • 奧羅莫拉西布：銷售預測
    • Inavoliciv：銷售預測
    • Volasidenib：銷售預測
    • STX-478：銷售預測
    • AZD 5363：銷售預測
    • AG-120：銷售預測
    • 塞帕替尼：銷售預測
    • ADI-PEG 20：銷售預測
    • Augtyro：銷售預測
    • Tarretrectinib：銷售預測
    • Piqray/Vijoice：銷售預測
    • TAS-120：銷售預測
    • 萊斯利迪亞：銷售預測
    • AG-221：銷售預測

第21章 結論

第22章：高階主管洞察

第23章附錄一：表格形式數據

第24章 附錄二：公司與組織列表

Product Code: RA100533

Cancer Metabolism Based Therapeutics Market: Overview

As per Roots Analysis, the cancer metabolism based therapeutics market is estimated to grow from USD 3.7 billion in the current year to USD 26.3 billion by 2035, at a CAGR of 24.3% during the forecast period, till 2035.

Cancer Metabolism Based Therapeutics Market: Growth and Trends

Cancer continues to represent a major global health burden, impacting millions of individuals annually. The progression and proliferation of cancer cells are driven by metabolic reprogramming, a process that enables these cells to utilize nutrients differently from normal cells. This reprogramming is characterized by alterations in key metabolic pathways, including elevated glucose absorption (associated with the Warburg effect), impaired mitochondrial function, and increased reliance on nutrients such as glutamine and lipids. These changes collectively define the distinct metabolic profile of cancer cells compared to healthy cells.

In the mid-20th century, the seminal work of Otto Warburg in cancer metabolism demonstrated that tumor tissues preferentially utilize aerobic glycolysis. This discovery catalyzed significant interest among both industry and academic stakeholders in targeting reprogrammed metabolic pathways critical for tumor survival. Subsequently, research efforts have focused on identifying and characterizing key enzymes involved in pathways such as the tricarboxylic acid (TCA) cycle, lipid biosynthesis, and amino acid, pentose phosphate, and nucleotide metabolism.

These foundational insights have driven the development and advancement of cancer metabolism-based therapeutics, which have shown promise in effectively targeting and disrupting tumor-specific metabolic pathways, thereby inhibiting uncontrolled cell proliferation. Supported by encouraging therapeutic outcomes, companies have entered into numerous strategic collaborations to accelerate research and development activities within the global cancer metabolism therapeutics market. As more candidates progress into late-stage clinical development, partnership activity is expected to intensify, supporting robust market growth in the coming years.

Growth Drivers: Strategic Enablers of Market Expansion

The growth of the cancer metabolism-based therapeutics market is being driven by the increasing adoption of precision medicine approaches that target the distinct metabolic pathways associated with individual tumor profiles, enabling the development of more personalized and effective treatment strategies. This shift is encouraging pharmaceutical companies to expand their research and development pipelines to address the rising demand for targeted cancer therapies. At the same time, the global cancer burden continues to increase significantly, with approximately 20 million new cases and over 10 million deaths reported in a single year, and projections suggesting that annual incidence could exceed 35 million cases by 2050 due to population growth and demographic trends. This escalating prevalence underscores the urgent need for innovative therapeutic solutions, such as cancer metabolism-based therapies, which focus on reprogrammed metabolic pathways in cancer cells and offer improved efficacy and a higher degree of personalization compared to conventional treatment approaches.

Market Challenges: Critical Barriers Impeding Progress

The cancer metabolism-based therapeutics market faces significant challenges due to limitations in target specificity and the inherent complexity of tumor metabolism. Many existing therapies demonstrate suboptimal target specificity and elevated toxicity, as cancerous and healthy cells often share overlapping metabolic pathways, leading to off-target effects. These issues contribute to high clinical trial failure rates, limited regulatory approvals, increased development costs, and constrained commercial viability. Furthermore, the metabolic plasticity of cancer cells presents an additional hurdle, enabling them to dynamically adapt to microenvironmental stresses such as nutrient deprivation and hypoxia. This adaptability complicates efforts to effectively target a single metabolic pathway, given the highly heterogeneous and flexible nature of tumor metabolism. As a result, conventional treatments such as chemotherapy and radiation therapy yield variable outcomes and are effective only in a subset of patients, owing to differences in genetic mutations and protein expression profiles. This variability underscores the critical need for advancing precision and personalized therapeutic approaches in oncology.

Cancer Metabolism Based Therapeutics Market: Key Insights

The report delves into the current state of the cancer metabolism based therapeutics market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • Currently, close to 250 cancer metabolism-based therapy programs are exploiting the unique metabolic vulnerabilities of tumor cells for targeting a wide range of cancer disease indications.
Cancer Metabolism Based Therapeutics Market - IMG1
  • Close to 90% of the cancer metabolism-based therapy programs are in clinical stages; majority (52%) of these programs are being investigated in phase II clinical trials.
  • A sizeable proportion of the trials (~30%) were registered in 2025; over 70% of the trials are currently recruiting potential candidates for the investigation of cancer metabolism-based therapies.
  • Around 65% of the agreements in the cancer metabolism-based therapies market were inked in the last two years; notably, majority (>50%) of the deals were inked by players headquartered in North America.
Cancer Metabolism Based Therapeutics Market - IMG2
  • Growing cancer burden, advancements in targeted therapies and increasing funding in R&D activities is driving market growth.
  • Owing to the rising prevalence of cancer along with significant advances in tumor metabolism research, the global cancer metabolism-based therapies market is anticipated to grow at a CAGR of 24.3% till 2035.
Cancer Metabolism Based Therapeutics Market - IMG3
  • The cancer metabolism-based therapies market in the US is expected to grow at a steady CAGR during the forecast period, due to the expanding clinical use and growing adoption of cancer metabolism-based therapies.
  • Owing to the presence of established market players, rapid increase in patients diagnosed with cancer, along with ongoing technological advancements, the cancer metabolism-based therapeutics market in the US is expected to witness substantial growth.

Cancer Metabolism based Therapeutics Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Modality

  • Small Molecules
  • Biologics

By Route of Administration

  • Oral
  • Intravenous
  • Intramuscular

By Target Disease Indication

  • Breast Cancer
  • Non-small Cell Lung Cancer
  • Acute Myeloid Leukemia
  • Brain Cancer
  • Cholangiocarcinoma
  • Bile Duct Cancer
  • Myelodysplastic Syndromes
  • Malignant-mesothelioma
  • Soft Tissue Sarcoma
  • Hepatocellular Carcinoma
  • Pancreatic Cancer

By Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

By Sales Forecast of Therapies

  • Daraxonrasib
  • Gedatolisib
  • Olomorasib
  • Inavolisib
  • Vorasidenib
  • STX-478
  • AZD 5363
  • AG-120
  • Selpercatinib
  • ADI-PEG 20
  • Augtyro
  • Taletrectinib
  • Piqray
  • TAS-120
  • Rezlidhia
  • AG-221

Cancer Metabolism Based Therapeutics Market: Key Segments

Which Route of Administration Accounts for the Largest Cancer Metabolism Based Therapeutics Market Share?

By 2035, the oral route of administration segment is expected to account for the largest share of the market, capturing approximately 85%, while also demonstrating strong growth throughout the forecast period. This dominance can be attributed to its non-invasive nature, ease of administration, and higher patient compliance compared to alternative delivery routes. Meanwhile, the intramuscular segment is projected to register a higher compound annual growth rate (CAGR), driven by its ability to enable controlled and sustained release of metabolic inhibitors over extended durations, thereby maintaining stable therapeutic drug levels and reducing dosing frequency.

Which Type of Modality Accounts for the Largest Share?

Based on market analysis, the small molecules segment is expected to capture the largest share of the Cancer Metabolism based Therapeutics Market by 2035. This dominance is driven by their demonstrated efficacy, ease of administration, cost-effective manufacturing, and well-established safety profiles.

Regional Market Analysis: Which Regions are Showing the Fastest Growth?

North America: Largest Regional Market

North America is projected to account for over 45% of the global market share by 2035, driven by the increasing demand for cancer metabolism-based therapies in the United States and the strong presence of established therapy developers in the region. Additionally, several leading manufacturers have expanded their development and production capabilities in recent years to address the growing regional demand.

Asia-Pacific: Fastest Growing Regional Market

The Asia-Pacific market in Cancer Metabolism based Therapeutics Market is anticipated to register a higher CAGR through 2035, supported by increasing investments in research and development of novel cancer metabolism-based therapies and regulatory frameworks that favor developers with specialized capabilities. Additionally, the region's expanding patient population is enlarging the addressable market for pharmaceuticals and healthcare products, thereby driving overall market growth.

Example Players in Cancer Metabolism based Therapeutics Market

  • Bristol Myers Squibb
  • Eli Lilly
  • Novartis
  • Polaris
  • Roche

Cancer Metabolism Based Therapeutics Market: Research Coverage

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the Cancer Metabolism based Therapeutics Market, focusing on key market segments, including [A] type of modality, [B] route of administration, [C] target disease indication, [D] geographical regions, and [E] sales forecast of therapies.
  • Cancer Metabolism-Based Therapies Market Landscape: A detailed assessment of the overall cancer metabolism-based therapies market landscape, along with information on several relevant parameters, such as [A] metabolic pathway, [B] target, [C] target disease indication, [D] route of administration, [E] type of modality, [F] type of therapy, [G] drug designation, [H] year of establishment [I] company size, and [J] location of headquarters.
  • Company Profiles: In-depth profiles of key companies based in North America, Europe and Asia-Pacific based on several parameters such as [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
  • Clinical Trial Analysis: An in-depth analysis of completed and ongoing clinical trials investigating cancer metabolism-based therapies, based on several relevant parameters, such as [A] trial registration year, [B] trial status, [C] trial phase, [D] patients enrolled, [E] trial study design, [F] type of sponsor, [G] patient gender, [H] most active industry and non-industry players and [I] geographical distribution.
  • Partnerships and Collaborations Analysis: An analysis of the partnerships that have been inked by stakeholders engaged in this domain. It includes a brief description of various partnership models and includes a detailed analysis of partnerships based on [A] year of partnership, [B] type of partnership, and [C] geographical analysis.
  • Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of the market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges in this domain.

Key Questions Answered in this Report

  • Which are the leading companies in the Cancer Metabolism based Therapeutics Market?
  • Which region dominates the Cancer Metabolism based Therapeutics Market?
  • What are the key trends observed in the Cancer Metabolism based Therapeutics Market?
  • What factors are likely to influence the evolution of this market?
  • What are the primary challenges faced by cancer metabolism-based therapeutic developers?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
  • The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
  • The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
  • The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
  • The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. BACKGROUND

  • 1.1. Context
  • 1.2. Project Objectives

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases
  • 2.5. Robust Quality Control

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Major Currencies Affecting the Market
      • 4.2.2.2. Factors Affecting Currency Fluctuations
      • 4.2.2.3. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Currency Exchange Rate
      • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
      • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
    • 4.2.6. Interest Rates
      • 4.2.6.1. Interest Rates and Their Impact on the Market
      • 4.2.6.2. Strategies for Managing Interest Rate Risk
    • 4.2.7. Commodity Flow Analysis
      • 4.2.7.1. Type of Commodity
      • 4.2.7.2. Origins and Destinations
      • 4.2.7.3. Values and Weights
      • 4.2.7.4. Modes of Transportation
    • 4.2.8. Global Trade Dynamics
      • 4.2.8.1. Import Scenario
      • 4.2.8.2. Export Scenario
      • 4.2.8.3. Trade Policies
      • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
      • 4.2.8.5. Impact of Trade Barriers on the Market
    • 4.2.9. War Impact Analysis
      • 4.2.9.1. Russian-Ukraine War
      • 4.2.9.2. Israel-Hamas War
    • 4.2.10. COVID Impact / Related Factors
      • 4.2.10.1. Global Economic Impact
      • 4.2.10.2. Industry-specific Impact
      • 4.2.10.3. Government Response and Stimulus Measures
      • 4.2.10.4. Future Outlook and Adaptation Strategies
    • 4.2.11. Other Indicators
      • 4.2.11.1. Fiscal Policy
      • 4.2.11.2. Consumer Spending
      • 4.2.11.3. Gross Domestic Product
      • 4.2.11.4. Employment
      • 4.2.11.5. Taxes
      • 4.2.11.6. Stock Market Performance
      • 4.2.11.7. Cross Border Dynamics
  • 4.3. Conclusion

5. EXECUTIVE SUMMARY

  • 5.1. Executive Summary: Market Landscape
  • 5.2. Executive Summary: Market Trends
  • 5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

  • 6.1. Overview of Cancer Metabolism-Based Therapies
  • 6.2. Key Metabolic Alterations Associated with Cancer Cells
  • 6.3. Core Metabolic Pathways Associated with Cancer
  • 6.4. Advantages of Cancer Metabolism-Based Therapies
  • 6.5. Challenges Associated with Cancer Metabolism-Based Therapies
  • 6.6. Future Outlook

7. MARKET LANDSCAPE

  • 7.1. Methodology and Key Parameters
  • 7.2. Cancer Metabolism-Based Therapies: Overall Market Landscape
    • 7.2.1. Analysis by Stage of Development
    • 7.2.2. Analysis by Metabolic Pathway
    • 7.2.3. Analysis by Target
    • 7.2.4. Analysis by Target Disease Indication
    • 7.2.5. Analysis by Route of Administration
    • 7.2.6. Analysis by Type of Modality
    • 7.2.7. Analysis by Type of Therapy
    • 7.2.8. Analysis by Drug Designation
  • 7.3. Cancer Metabolism-Based Therapies: Developer Landscape
    • 7.3.1. Analysis by Year of Establishment
    • 7.3.2. Analysis by Company Size
    • 7.3.3. Analysis by Location of Headquarters
    • 7.3.4. Analysis by Company Size and Location of Headquarters
    • 7.3.5. Most Active Players: Analysis by Number of Therapies Developed

8. COMPANY PROFILES

  • 8.1. Chapter Overview
  • 8.2. AstraZeneca
    • 8.2.1. Company Details
    • 8.2.2. Cancer Metabolism-Based Drugs Portfolio
    • 8.2.3. Key Initiatives
  • 8.3. Bristol Myers Squibb
    • 8.3.1. Company Details
    • 8.3.2. Cancer Metabolism-Based Drugs Portfolio
    • 8.3.3. Key Initiatives
  • 8.4. Cornerstone Pharmaceuticals
    • 8.4.1. Company Details
    • 8.4.2. Cancer Metabolism-Based Drugs Portfolio
    • 8.4.3. Key Initiatives
  • 8.5. Eli Lilly
    • 8.5.1. Company Details
    • 8.5.2. Cancer Metabolism-Based Drugs Portfolio
    • 8.5.3. Key Initiatives
  • 8.6. Novartis
    • 8.6.1. Company Details
    • 8.6.2. Cancer Metabolism-Based Drugs Portfolio
    • 8.6.3. Key Initiatives
  • 8.7. Polaris
    • 8.7.1. Company Details
    • 8.7.2. Cancer Metabolism-Based Drugs Portfolio
    • 8.7.3. Key Initiatives
  • 8.8. Roche
    • 8.8.1. Company Details
    • 8.8.2. Cancer Metabolism-Based Drugs Portfolio
    • 8.8.3. Key Initiatives
  • 8.9. Servier
    • 8.9.1. Company Details
    • 8.9.2. Cancer Metabolism-Based Drugs Portfolio
    • 8.9.3. Key Initiatives

9. CLINICAL TRIAL ANALYSIS

  • 9.1. Methodology and Key Parameters
  • 9.2. Cancer Metabolism-Based Therapies: Clinical Trial Analysis
    • 9.2.1. Analysis by Trial Registration Year
    • 9.2.2. Analysis by Trial Status
    • 9.2.3. Analysis by Trial Registration Year and Trial Status
    • 9.2.4. Analysis by Number of Patients Enrolled and Trial Registration Year
    • 9.2.5. Analysis by Number of Patients Enrolled and Trial Status
    • 9.2.6. Analysis by Trial Phase
    • 9.2.7. Analysis by Number of Patients Enrolled and Trial Phase
    • 9.2.8. Analysis by Study Design
      • 9.2.8.1. Analysis by Design Masking
      • 9.2.8.2. Analysis by Type of Intervention Model
      • 9.2.8.3. Analysis by Trial Purpose
      • 9.2.8.4. Analysis by Type of Allocation
    • 9.2.9. Analysis by Type of Sponsor / Collaborator
    • 9.2.10. Analysis by Patient Gender
    • 9.2.11. Most Active Industry Players: Analysis by Number of Clinical Trials
    • 9.2.12. Most Active Non-Industry Players: Analysis by Number of Clinical Trials
    • 9.2.13. Analysis by Geography
      • 9.2.13.1. Analysis of Clinical Trials by Trial Status, Trial Phase and Geography
      • 9.2.13.2. Analysis of Clinical Trials by Trial Status and Geography
      • 9.2.13.3. Analysis of Clinical Trials by Patients Enrolled, Trial Status and Geography
    • 9.2.14. Geographical Distribution of Trials and Number of Patients Enrolled
      • 9.2.14.1. Clinical Trials in North America: Key Insights
      • 9.2.14.2. Clinical Trials in Europe: Key Insights
      • 9.2.14.3. Clinical Trials in Asia-Pacific: Key Insights
      • 9.2.14.4. Clinical Trials in Rest of the World: Key Insights

10. PARTNERSHIPS AND COLLABORATIONS

  • 10.1. Partnership Models
  • 10.2. Cancer Metabolism-Based Therapies: Partnerships and Collaborations
    • 10.2.1. Analysis by Year of Partnership
    • 10.2.2. Analysis by Type of Partnership
    • 10.2.3. Analysis by Year and Type of Partnership
    • 10.2.4. Analysis by Target Disease Indication
    • 10.2.5. Most Active Players: Analysis by Number of Partnerships
    • 10.2.6. Analysis by Geography
      • 10.2.6.1. Local and International Deals
      • 10.2.6.2. Intercontinental and Intracontinental Deals

11. MARKET IMPACT ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Market Drivers
  • 11.3. Market Restraints
  • 11.4. Market Opportunities
  • 11.5. Market Challenges

12. GLOBAL CANCER METABOLISM-BASED THERAPIES MARKET

  • 12.1. Forecast Methodology
  • 12.2. Key Assumptions
  • 12.3. Global Cancer Metabolism-Based Therapies Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 12.4. Multivariate Scenario Analysis
    • 12.4.1. Global Cancer Metabolism-Based Therapies Market, Forecasted Estimates (Till 2035), Conservative Scenario
    • 12.4.2. Global Cancer Metabolism-Based Therapies Market, Forecasted Estimates (Till 2035), Optimistic Scenario
  • 12.5. Key Market Segmentations

13. CANCER METABOLISM-BASED THERAPIES MARKET, BY TYPE OF MODALITY

  • 13.1. Cancer Metabolism-Based Therapies Market: Distribution by Type of Modality
    • 13.1.1. Cancer Metabolism-Based Therapies Market for Biologics: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 13.1.2. Cancer Metabolism-Based Therapies Market for Small Molecules: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 13.2. Data Triangulation and Validation

14. CANCER METABOLISM-BASED THERAPIES MARKET, BY ROUTE OF ADMINISTRATION

  • 14.1. Cancer Metabolism-Based Therapies Market: Distribution by Route of Administration
    • 14.1.1. Cancer Metabolism-Based Therapies Market for Oral Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 14.1.2. Cancer Metabolism-Based Therapies Market for Intramuscular Route: Forecasted Estimates (Till 2035)
    • 14.1.3. Cancer Metabolism-Based Therapies Market for Intravenous Route: Forecasted Estimates (Till 2035)
  • 14.2. Data Triangulation and Validation

15. CANCER METABOLISM-BASED THERAPIES MARKET: BY TARGET DISEASE INDICATION

  • 15.1. Cancer Metabolism-Based Therapies Market: Distribution by Target Disease Indication
    • 15.1.1.Cancer Metabolism-Based Therapies Market for Breast Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 15.1.2. Cancer Metabolism-Based Therapies Market for Non-small Cell Lung Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 15.1.3. Cancer Metabolism-Based Therapies Market for Acute Myeloid Leukemia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 15.1.4. Cancer Metabolism-Based Therapies Market for Brain Cancer: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035)
    • 15.1.5. Cancer Metabolism-Based Therapies Market for Cholangiocarcinoma: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 15.1.6. Cancer Metabolism-Based Therapies Market for Bile Duct Cancer: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 15.1.7. Cancer Metabolism-Based Therapies Market for Myelodysplastic Syndromes: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 15.1.8. Cancer Metabolism-Based Therapies Market for Malignant-mesothelioma: Forecasted Estimates (Till 2035)
    • 15.1.9. Cancer Metabolism-Based Therapies Market for Pancreatic Cancer: Forecasted Estimates (Till 2035)
    • 15.1.10. Cancer Metabolism-Based Therapies Market for Soft Tissue Sarcoma: Forecasted Estimates (Till 2035)
    • 15.1.11. Cancer Metabolism-Based Therapies Market for Hepatocellular Carcinoma: Forecasted Estimates (Till 2035)
  • 15.2. Data Triangulation and Validation

16. CANCER METABOLISM-BASED THERAPIES MARKET, BY GEOGRAPHY

  • 16.1. Cancer Metabolism-Based Therapies Market: Distribution by Geography
    • 16.1.1. Cancer Metabolism-Based Therapies Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
      • 16.1.1.1. Cancer Metabolism-Based Therapies Market in the US: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
      • 16.1.1.2. Cancer Metabolism-Based Therapies Market in Canada: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 16.1.2. Cancer Metabolism-Based Therapies Market in Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
      • 16.1.2.1. Cancer Metabolism-Based Therapies Market in Germany: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
      • 16.1.2.2. Cancer Metabolism-Based Therapies Market in the France: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
      • 16.1.2.3. Cancer Metabolism-Based Therapies Market in UK: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
      • 16.1.2.4. Cancer Metabolism-Based Therapies Market in Italy: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
      • 16.1.2.5. Cancer Metabolism-Based Therapies Market in Spain: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
      • 16.1.2.6. Cancer Metabolism-Based Therapies Market in Rest of Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 16.1.3. Cancer Metabolism-Based Therapies Market in Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
      • 16.1.3.1. Cancer Metabolism-Based Therapies Market in China: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
      • 16.1.3.2. Cancer Metabolism-Based Therapies Market in Japan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
      • 16.1.3.3. Cancer Metabolism-Based Therapies Market in India: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
      • 16.1.3.4. Cancer Metabolism-Based Therapies Market in South Korea: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
      • 16.1.3.5. Cancer Metabolism-Based Therapies Market in Rest of Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
      • 16.1.3.6. Cancer Metabolism-Based Therapies Market in Rest of the World: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17. CANCER METABOLISM-BASED THERAPIES MARKET, NORTH AMERICA

  • 17.1. Cancer Metabolism-Based Therapies Market in North America: Distribution by Type of Modality
    • 17.1.1. Cancer Metabolism-Based Therapies Market in North America for Biologics: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 17.1.2. Cancer Metabolism-Based Therapies Market in North America for Small Molecules: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 17.2. Cancer Metabolism-Based Therapies Market in North America: Distribution by Route of Administration
    • 17.2.1. Cancer Metabolism-Based Therapies Market in North America for Oral Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 17.2.2. Cancer Metabolism-Based Therapies Market in North America for Intramuscular Route: Forecasted Estimates (Till 2035)
    • 17.2.3. Cancer Metabolism-Based Therapies Market in North America for Intravenous Route: Forecasted Estimates (Till 2035)
  • 17.3. Cancer Metabolism-Based Therapies Market in North America: Distribution by Target Disease Indication
    • 17.3.1. Cancer Metabolism-Based Therapies Market in North America for Breast Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 17.3.2. Cancer Metabolism-Based Therapies Market in North America for Non-small Cell Lung Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 17.3.3. Cancer Metabolism-Based Therapies Market in North America for Acute Myeloid Leukemia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 17.3.4. Cancer Metabolism-Based Therapies Market in North America for Brain Cancer: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035)
    • 17.3.5. Cancer Metabolism-Based Therapies Market in North America for Cholangiocarcinoma: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 17.3.6. Cancer Metabolism-Based Therapies Market in North America for Bile Duct Cancer: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 17.3.7. Cancer Metabolism-Based Therapies Market in North America for Myelodysplastic Syndromes: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 17.3.8. Cancer Metabolism-Based Therapies Market in North America for Malignant-mesothelioma: Forecasted Estimates (Till 2035)
    • 17.3.9. Cancer Metabolism-Based Therapies Market in North America for Pancreatic Cancer: Forecasted Estimates (Till 2035)
    • 17.3.10. Cancer Metabolism-Based Therapies Market in North America for Soft Tissue Sarcoma: Forecasted Estimates (Till 2035)
    • 17.3.11. Cancer Metabolism-Based Therapies Market in North America for Hepatocellular Carcinoma: Forecasted Estimates (Till 2035)

18. CANCER METABOLISM-BASED THERAPIES MARKET, EUROPE

  • 18.1. Cancer Metabolism-Based Therapies Market in Europe: Distribution by Type of Modality
    • 18.1.1. Cancer Metabolism-Based Therapies Market in Europe for Biologics: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 18.1.2. Cancer Metabolism-Based Therapies Market in Europe for Small Molecules: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 18.2. Cancer Metabolism-Based Therapies Market in Europe: Distribution by Route of Administration
    • 18.2.1. Cancer Metabolism-Based Therapies Market in Europe for Oral Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 18.2.2. Cancer Metabolism-Based Therapies Market in Europe for Intramuscular Route: Forecasted Estimates (Till 2035)
    • 18.2.3. Cancer Metabolism-Based Therapies Market in Europe for Intravenous Route: Forecasted Estimates (Till 2035)
  • 18.3. Cancer Metabolism-Based Therapies Market in Europe: Distribution by Target Disease Indication
    • 18.3.1. Cancer Metabolism-Based Therapies Market in Europe for Breast Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 18.3.2. Cancer Metabolism-Based Therapies Market in Europe for Non-small Cell Lung Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 18.3.3. Cancer Metabolism-Based Therapies Market in Europe for Acute Myeloid Leukemia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 18.3.4. Cancer Metabolism-Based Therapies Market in Europe for Brain Cancer: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035)
    • 18.3.5. Cancer Metabolism-Based Therapies Market in Europe for Cholangiocarcinoma: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 18.3.6. Cancer Metabolism-Based Therapies Market in Europe for Bile Duct Cancer: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 18.3.7. Cancer Metabolism-Based Therapies Market in Europe for Myelodysplastic Syndromes: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 18.3.8. Cancer Metabolism-Based Therapies Market in Europe for Malignant-mesothelioma: Forecasted Estimates (Till 2035)
    • 18.3.9. Cancer Metabolism-Based Therapies Market in Europe for Pancreatic Cancer: Forecasted Estimates (Till 2035)
    • 18.3.10. Cancer Metabolism-Based Therapies Market in Europe for Soft Tissue Sarcoma: Forecasted Estimates (Till 2035)
    • 18.3.11. Cancer Metabolism-Based Therapies Market in Europe for Hepatocellular Carcinoma: Forecasted Estimates (Till 2035)

19. CANCER METABOLISM-BASED THERAPIES MARKET, ASIA-PACIFIC

  • 19.1. Cancer Metabolism-Based Therapies Market in Asia-Pacific: Distribution by Type of Modality
    • 19.1.1. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Biologics: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 19.1.2. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Small Molecules: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.2. Cancer Metabolism-Based Therapies Market in Asia-Pacific: Distribution by Route of Administration
    • 19.2.1. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Oral Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 19.2.2. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Intramuscular Route: Forecasted Estimates (Till 2035)
    • 19.2.3. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Intravenous Route: Forecasted Estimates (Till 2035)
  • 19.3. Cancer Metabolism-Based Therapies Market in Asia-Pacific: Distribution by Target Disease Indication
    • 19.3.1. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Breast Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 19.3.2. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Non-small Cell Lung Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 19.3.3. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Acute Myeloid Leukemia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 19.3.4. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Brain Cancer: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035)
    • 19.3.5. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Cholangiocarcinoma: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 19.3.6. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Bile Duct Cancer: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 19.3.7. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Myelodysplastic Syndromes: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 19.3.8. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Malignant-mesothelioma: Forecasted Estimates (Till 2035)
    • 19.3.9. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Pancreatic Cancer: Forecasted Estimates (Till 2035)
    • 19.3.10. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Soft Tissue Sarcoma: Forecasted Estimates (Till 2035)
    • 19.3.11. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Hepatocellular Carcinoma: Forecasted Estimates (Till 2035)

Detailed segment-wise distribution across individual regions is available in supporting excel data packs

20. CANCER METABOLISM-BASED THERAPIES MARKET, SALES FORECAST OF DRUGS

  • 20.1. Approved Cancer Metabolism-Based Therapies: Sales Forecast
    • 20.1.1. Daraxonrasib: Sales Forecast
    • 20.1.2. Gedatolisib: Sales Forecast
    • 20.1.3. Olomorasib: Sales Forecast
    • 20.1.4. Inavolisib: Sales Forecast
    • 20.1.5. Vorasidenib: Sales Forecast
    • 20.1.6. STX-478: Sales Forecast
    • 20.1.7. AZD 5363: Sales Forecast
    • 20.1.8. AG-120: Sales Forecast
    • 20.1.9. Selpercatinib: Sales Forecast
    • 20.1.10. ADI-PEG 20: Sales Forecast
    • 20.1.11. Augtyro: Sales Forecast
    • 20.1.12. Taletrectinib: Sales Forecast
    • 20.1.13. Piqray / Vijoice: Sales Forecast
    • 20.1.14. TAS-120: Sales Forecast
    • 20.1.15. Rezlidhia: Sales Forecast
    • 20.1.16. AG-221: Sales Forecast

21. CONCLUDING REMARKS

22. EXECUTIVE INSIGHTS

  • 22.1. Chapter Overview
  • 22.2. Company A
    • 22.2.1. Company Snapshot
    • 22.2.2. Interview Transcript: Associate Professor
  • 22.3. Company B
    • 22.3.1. Company Snapshot
    • 22.3.2. Interview Transcript: Medical Oncologist
  • 22.4. Company C
    • 22.4.1. Company Snapshot
    • 22.4.2. Interview Transcript: Associate Professor

23. APPENDIX I: TABULATED DATA

24. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 7.1 List of Cancer Metabolism-Based Therapy Programs
  • Table 7.2 List of Cancer Metabolism-Based Therapies Developers
  • Table 9.1 Cancer Metabolism-Based Therapies: List of Clinical Trials
  • Table 10.1 Cancer Metabolism-Based Therapies: List of Partnership and Collaborations
  • Table 12.1 Global Cancer Metabolism-Based Therapies Market, till 2035: List of Cancer Metabolism-based Therapies Forecasted
  • Table 23.1 Cancer Metabolism-Based Therapies: Distribution by Stage of Development
  • Table 23.2 Cancer Metabolism-Based Therapies: Distribution by Metabolic Pathway
  • Table 23.3 Cancer Metabolism-Based Therapies: Distribution by Target
  • Table 23.4 Cancer Metabolism-Based Therapies: Distribution by Therapeutic Indication
  • Table 23.5 Cancer Metabolism-Based Therapies: Distribution by Route of Administration
  • Table 23.6 Cancer Metabolism-Based Therapies: Distribution by Type of Modality
  • Table 23.7 Cancer Metabolism-Based Therapies: Distribution by Type of Therapy
  • Table 23.8 Cancer Metabolism-Based Therapies: Distribution by Drug Designation
  • Table 23.9 Cancer Metabolism-Based Therapy Developers: Distribution by Year of Establishment
  • Table 23.10 Cancer Metabolism-Based Therapy Developers: Distribution by Company Size
  • Table 23.11 Cancer Metabolism-Based Therapy Developers: Distribution by Location of Headquarters
  • Table 23.12 Cancer Metabolism-Based Therapy Developers: Distribution by Company Size and Location of Headquarters
  • Table 23.13 Most Active Players: Analysis by Number of Therapies
  • Table 23.14 Clinical Trial Analysis: Distribution by Trial Registration Year
  • Table 23.15 Clinical Trial Analysis: Distribution by Trial Status
  • Table 23.16 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Table 23.17 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
  • Table 23.18 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
  • Table 23.19 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 23.20 Clinical Trial Analysis: Distribution by Patients Enrolled and Trial Phase
  • Table 23.21 Clinical Trial Analysis: Distribution by Study Design
  • Table 23.22 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Table 23.23 Clinical Trial Analysis: Distribution by Patient Gender
  • Table 23.24 Most Active Industry Players: Distribution by Number of Trials
  • Table 23.25 Most Active Non-Industry Players: Distribution by Number of Registered Trials
  • Table 23.26 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
  • Table 23.27 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
  • Table 23.28 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
  • Table 23.29 Clinical Trial Analysis in North America: Key Insights
  • Table 23.30 Clinical Trial Analysis in Europe: Key Insights
  • Table 23.31 Clinical Trial Analysis in Asia-Pacific: Key Insights
  • Table 23.32 Clinical Trial Analysis in Rest of the World: Key Insights
  • Table 23.33 Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 23.34 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 23.35 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 23.36 Partnerships and Collaborations: Distribution by Target Disease Indication
  • Table 23.37 Most Active Players: Distribution by Number of Partnerships
  • Table 23.38 Partnerships and Collaborations: Local and International Deals
  • Table 23.39 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
  • Table 23.40 Global Cancer Metabolism-Based Therapies Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.41 Global Cancer Metabolism-Based Therapies Market, Forecasted Estimates (Till 2035) (USD Billion), Conservative Scenario
  • Table 23.42 Global Cancer Metabolism-Based Therapies Market, Forecasted Estimates (Till 2035) (USD Billion), Optimistic Scenario
  • Table 23.43 Cancer Metabolism-Based Therapies Market: Distribution by Type of Modality
  • Table 23.44 Cancer Metabolism-Based Therapies Market for Biologics, Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.45 Cancer Metabolism-Based Therapies Market for Small Molecules, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.46 Cancer Metabolism-Based Therapies Market: Distribution by Route of Administration
  • Table 23.47 Cancer Metabolism-Based Therapies Market for Oral Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.48 Cancer Metabolism-Based Therapies Market for Intramuscular Route, Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.49 Cancer Metabolism-Based Therapies Market for Intravenous Route, Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.50 Cancer Metabolism-Based Therapies Market: Distribution by Target Disease Indication
  • Table 23.51 Cancer Metabolism-Based Therapies Market for Breast Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.52 Cancer Metabolism-Based Therapies Market for Non-small Cell Lung Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.53 Cancer Metabolism-Based Therapies Market for Acute Myeloid Leukemia, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.54 Cancer Metabolism-Based Therapies Market for Brain Cancer, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.55 Cancer Metabolism-Based Therapies Market for Cholangiocarcinoma, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.56 Cancer Metabolism-Based Therapies Market for Bile Duct Cancer, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.57 Cancer Metabolism-Based Therapies Market for Myelodysplastic Syndromes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.58 Cancer Metabolism-Based Therapies Market for Malignant-mesothelioma, Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.59 Cancer Metabolism-Based Therapies Market for Pancreatic Cancer, Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.60 Cancer Metabolism-Based Therapies Market for Soft Tissue Sarcoma, Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.61 Cancer Metabolism-Based Therapies Market for Hepatocellular Cancer, Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.62 Cancer Metabolism-Based Therapies Market: Distribution by Geographical Regions
  • Table 23.63 Cancer Metabolism-Based Therapies Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.64 Cancer Metabolism-Based Therapies Market in US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.65 Cancer Metabolism-Based Therapies Market in Canada, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.66 Cancer Metabolism-Based Therapies Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.67 Cancer Metabolism-Based Therapies Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.68 Cancer Metabolism-Based Therapies Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.69 Cancer Metabolism-Based Therapies Market in UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.70 Cancer Metabolism-Based Therapies Market in Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.71 Cancer Metabolism-Based Therapies Market in Spain, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.72 Cancer Metabolism-Based Therapies Market in Rest of Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.73 Cancer Metabolism-Based Therapies Market in Asia-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.74 Cancer Metabolism-Based Therapies Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.75 Cancer Metabolism-Based Therapies Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.76 Cancer Metabolism-Based Therapies Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.77 Cancer Metabolism-Based Therapies Market in South Korea, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.78 Cancer Metabolism-Based Therapies Market in Rest of Asia-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.79 Cancer Metabolism-Based Therapies Market in Rest of the World, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.80 Cancer Metabolism-Based Therapies Market Daraxonrasib, Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.81 Cancer Metabolism-Based Therapies Market Gedatolisib, Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.82 Cancer Metabolism-Based Therapies Market Olomorasib, Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.83 Cancer Metabolism-Based Therapies Market Inavolisib, Historical Trends (Since 2025) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.84 Cancer Metabolism-Based Therapies Market Vorasidenib, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.85 Cancer Metabolism-Based Therapies Market STX-478, Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.86 Cancer Metabolism-Based Therapies Market AZD 5363, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.87 Cancer Metabolism-Based Therapies Market AG-120, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.88 Cancer Metabolism-Based Therapies Market Selpercatinib, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.89 Cancer Metabolism-Based Therapies Market ADI-PEG 20, Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.90 Cancer Metabolism-Based Therapies Market AUGTYRO, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.91 Cancer Metabolism-Based Therapies Market Taletrectinib, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.92 Cancer Metabolism-Based Therapies Market Piqray / Vijoice, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.93 Cancer Metabolism-Based Therapies Market TAS-120, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.94 Cancer Metabolism-Based Therapies Market REZLIDHIA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 23.95 Cancer Metabolism-Based Therapies Market AG-221, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Data Sources for Secondary Research
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 3.1 Market Dynamics: Forecast Methodology
  • Figure 3.2 Market Dynamics: Market Assessment Framework
  • Figure 4.1 Lessons Learnt from Past Recessions
  • Figure 5.1 Executive Summary: Market Landscape
  • Figure 5.2 Executive Summary: Market Trends
  • Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 7.1 Cancer Metabolism-based Therapy Programs: Distribution by Stage of Development
  • Figure 7.2 Cancer Metabolism-based Therapy Programs: Distribution by Metabolic Pathway
  • Figure 7.3 Cancer Metabolism-based Therapy Programs: Distribution by Target
  • Figure 7.4 Cancer Metabolism-based Therapy Programs: Distribution by Target Disease Indication
  • Figure 7.5 Cancer Metabolism-based Therapy Programs: Distribution by Route of Administration
  • Figure 7.6 Cancer Metabolism-based Therapy Programs: Distribution by Type of Modality
  • Figure 7.7 Cancer Metabolism-based Therapy Programs: Distribution by Type of Therapy
  • Figure 7.8 Cancer Metabolism-based Therapy Programs: Distribution by Drug Designation
  • Figure 7.9 Cancer Metabolism-based Therapy Developers: Distribution by Year of Establishment
  • Figure 7.10 Cancer Metabolism-based Therapy Developers: Distribution by Company Size
  • Figure 7.11 Cancer Metabolism-based Therapy Developers: Distribution by Location of Headquarters
  • Figure 7.12 Cancer Metabolism-based Therapy Developers: Distribution by Company Size and Location of Headquarters
  • Figure 7.13 Most Active Players: Analysis by Number of Therapies
  • Figure 9.1 Clinical Trial Analysis: Distribution by Trial Registration Year
  • Figure 9.2 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 9.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Figure 9.4 Clinical Trial Analysis: Distribution by Patients Enrolled by Trial Registration Year
  • Figure 9.5 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status
  • Figure 9.6 Clinical Trial Analysis: Distribution of Trials by Trial Phase
  • Figure 9.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Figure 9.8 Clinical Trial Analysis: Distribution by Study Design
  • Figure 9.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 9.10 Clinical Trial Analysis: Distribution by Patient Gender
  • Figure 9.11 Most Active Industry Players: Distribution by Number of Registered Trials
  • Figure 9.12 Most Active Non-Industry Players: Distribution by Number of Registered Trials
  • Figure 9.13 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
  • Figure 9.14 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
  • Figure 9.15 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
  • Figure 9.16 Clinical Trial Analysis: Geographical Distribution of Trials and Number of Patients Enrolled
  • Figure 9.17 Clinical Trial Analysis in North America: Key Insights
  • Figure 9.18 Clinical Trial Analysis in Europe: Key Insights
  • Figure 9.19 Clinical Trial Analysis in Asia-Pacific: Key Insights
  • Figure 9.20 Clinical Trial Analysis in Rest of the World: Key Insights
  • Figure 10.1 Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 10.4 Partnerships and Collaborations: Distribution by Target Disease Indication
  • Figure 10.5 Most Active Players: Distribution by Number of Partnerships
  • Figure 10.6 Partnerships and Collaborations: Local and International Deals
  • Figure 10.7 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
  • Figure 10.8 Partnerships and Collaborations: Recent Examples
  • Figure 12.1 Global Cancer Metabolism-Based Therapies Market: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 12.2 Global Cancer Metabolism-Based Therapies Market: Forecasted Estimates (Till 2035) (USD Billion), Conservative Scenario
  • Figure 12.3 Global Cancer Metabolism-Based Therapies Market: Forecasted Estimates (Till 2035) (USD Billion), Optimistic Scenario
  • Figure 13.1 Cancer Metabolism-Based Therapies Market for Biologics: Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 13.2 Cancer Metabolism-Based Therapies Market for Small Molecules: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • Figure 14.1 Cancer Metabolism-Based Therapies Market for Oral Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 14.2 Cancer Metabolism-Based Therapies Market for Intramuscular Route: Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 14.3 Cancer Metabolism-Based Therapies Market for Intravenous Route: Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 15.1 Cancer Metabolism-Based Therapies Market for Breast Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 15.2 Cancer Metabolism-Based Therapies Market for Non-small Cell Lung Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 15.3 Cancer Metabolism-Based Therapies Market for Acute Myeloid Leukemia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 15.4 Cancer Metabolism-Based Therapies Market for Brain Cancer: Historical Trends (Since 2024) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 15.5 Cancer Metabolism-Based Therapies Market for Cholangiocarcinoma: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 15.6 Cancer Metabolism-Based Therapies Market for Bile Duct Cancer: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 15.7 Cancer Metabolism-Based Therapies Market for Myelodysplastic Syndromes: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 15.8 Cancer Metabolism-Based Therapies Market for Others: Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 15.9 Cancer Metabolism-Based Therapies Market for Malignant-mesothelioma: Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 15.10 Cancer Metabolism-Based Therapies Market for Pancreatic Cancer: Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 15.11 Cancer Metabolism-Based Therapies Market for Soft Tissue Sarcoma: Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 15.12 Cancer Metabolism-Based Therapies Market for Hepatocellular Cancer: Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 16.1 Cancer Metabolism-Based Therapies Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 16.2 Cancer Metabolism-Based Therapies Market in US: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 16.3 Cancer Metabolism-Based Therapies Market in Canada: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 16.4 Cancer Metabolism-Based Therapies Market in Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 16.5 Cancer Metabolism-Based Therapies Market in Germany: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 16.6 Cancer Metabolism-Based Therapies Market in France: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 16.7 Cancer Metabolism-Based Therapies Market in UK: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 16.8 Cancer Metabolism-Based Therapies Market in Italy: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 16.9 Cancer Metabolism-Based Therapies Market in Spain: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 16.10 Cancer Metabolism-Based Therapies Market in Rest of Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 16.11 Cancer Metabolism-Based Therapies Market in Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 16.12 Cancer Metabolism-Based Therapies Market in China: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 16.13 Cancer Metabolism-Based Therapies Market in Japan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 16.14 Cancer Metabolism-Based Therapies Market in India: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 16.15 Cancer Metabolism-Based Therapies Market in South Korea: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 16.16 Cancer Metabolism-Based Therapies Market in Rest of Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 16.17 Cancer Metabolism-Based Therapies Market in Rest of the World: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 17.1 Cancer Metabolism-Based Therapies Market Daraxonrasib: Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 17.2 Cancer Metabolism-Based Therapies Market Gedatolisib: Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 17.3 Cancer Metabolism-Based Therapies Market Olomorasib: Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 17.4 Cancer Metabolism-Based Therapies Market Inavolisib: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 17.5 Cancer Metabolism-Based Therapies Market Vorasidenib: Historical Trends (Since 2024) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 17.6 Cancer Metabolism-Based Therapies Market STX-478: Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 17.7 Cancer Metabolism-Based Therapies Market AZD 5363: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 17.8 Cancer Metabolism-Based Therapies Market AG-120: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 17.9 Cancer Metabolism-Based Therapies Market Selpercatinib: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 17.10 Cancer Metabolism-Based Therapies Market ADI-PEG 20: Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 17.11 Cancer Metabolism-Based Therapies Market AUGTYRO: Historical Trends (Since 2024) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 17.12 Cancer Metabolism-Based Therapies Market Taletrectinib: Historical Trends (Since 2024) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 17.13 Cancer Metabolism-Based Therapies Market Piqray / Vijoice: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 17.14 Cancer Metabolism-Based Therapies Market TAS-120: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 17.15 Cancer Metabolism-Based Therapies Market REZLIDHIA: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 17.16 Cancer Metabolism-Based Therapies Market AG-221: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)